Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Lung Cancer Market

ID: MRFR/HC/0679-CR
200 Pages
Nidhi Mandole
Last Updated: May 07, 2026

Lung Cancer Market Research Report: Size, Share, Trend Analysis By Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy), By Diagnosis Type (Imaging Tests, Biopsy, Sputum Cytology, Blood Tests), By Patient Demographics (Age, Gender, Smoking History, Geographic Location), By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Lung Cancer Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Treatment Type (USD Billion) | |
      1. 4.1.1 Chemotherapy | |
      2. 4.1.2 Radiation Therapy | |
      3. 4.1.3 Targeted Therapy | |
      4. 4.1.4 Immunotherapy |
    2. 4.2 Healthcare, BY Diagnosis Type (USD Billion) | |
      1. 4.2.1 Imaging Tests | |
      2. 4.2.2 Biopsy | |
      3. 4.2.3 Sputum Cytology | |
      4. 4.2.4 Blood Tests |
    3. 4.3 Healthcare, BY Patient Demographics (USD Billion) | |
      1. 4.3.1 Age | |
      2. 4.3.2 Gender | |
      3. 4.3.3 Smoking History | |
      4. 4.3.4 Geographic Location |
    4. 4.4 Healthcare, BY Stage of Cancer (USD Billion) | |
      1. 4.4.1 Early Stage | |
      2. 4.4.2 Locally Advanced Stage | |
      3. 4.4.3 Metastatic Stage |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Roche (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Bristol-Myers Squibb (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Merck & Co. (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 AstraZeneca (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Novartis (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Pfizer (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Eli Lilly and Company (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Amgen (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 GSK (GB) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE |
    7. 6.4 US MARKET ANALYSIS BY DIAGNOSIS TYPE |
    8. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    9. 6.6 US MARKET ANALYSIS BY STAGE OF CANCER |
    10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    13. 6.10 CANADA MARKET ANALYSIS BY STAGE OF CANCER |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    18. 6.15 GERMANY MARKET ANALYSIS BY STAGE OF CANCER |
    19. 6.16 UK MARKET ANALYSIS BY TREATMENT TYPE |
    20. 6.17 UK MARKET ANALYSIS BY DIAGNOSIS TYPE |
    21. 6.18 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    22. 6.19 UK MARKET ANALYSIS BY STAGE OF CANCER |
    23. 6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    26. 6.23 FRANCE MARKET ANALYSIS BY STAGE OF CANCER |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    30. 6.27 RUSSIA MARKET ANALYSIS BY STAGE OF CANCER |
    31. 6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    34. 6.31 ITALY MARKET ANALYSIS BY STAGE OF CANCER |
    35. 6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    38. 6.35 SPAIN MARKET ANALYSIS BY STAGE OF CANCER |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY STAGE OF CANCER |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    47. 6.44 CHINA MARKET ANALYSIS BY STAGE OF CANCER |
    48. 6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    51. 6.48 INDIA MARKET ANALYSIS BY STAGE OF CANCER |
    52. 6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    55. 6.52 JAPAN MARKET ANALYSIS BY STAGE OF CANCER |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY STAGE OF CANCER |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY STAGE OF CANCER |
    64. 6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    67. 6.64 THAILAND MARKET ANALYSIS BY STAGE OF CANCER |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    71. 6.68 INDONESIA MARKET ANALYSIS BY STAGE OF CANCER |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY STAGE OF CANCER |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    80. 6.77 BRAZIL MARKET ANALYSIS BY STAGE OF CANCER |
    81. 6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    84. 6.81 MEXICO MARKET ANALYSIS BY STAGE OF CANCER |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY STAGE OF CANCER |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGE OF CANCER |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY STAGE OF CANCER |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY STAGE OF CANCER |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY STAGE OF CANCER |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY STAGE OF CANCER, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Chemotherapy
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy

Healthcare By Diagnosis Type (USD Billion, 2025-2035)

  • Imaging Tests
  • Biopsy
  • Sputum Cytology
  • Blood Tests

Healthcare By Patient Demographics (USD Billion, 2025-2035)

  • Age
  • Gender
  • Smoking History
  • Geographic Location

Healthcare By Stage of Cancer (USD Billion, 2025-2035)

  • Early Stage
  • Locally Advanced Stage
  • Metastatic Stage

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions